- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: Sexual maturation.
Displaying page 1 of 3.
EudraCT Number: 2021-006766-21 | Sponsor Protocol Number: MINI-SPIOMET | Start Date*: 2022-09-02 | |||||||||||
Sponsor Name:Hospital de Girona Dr. Josep Trueta | |||||||||||||
Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study. | |||||||||||||
Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005644-11 | Sponsor Protocol Number: 2-54-52014-143 | Start Date*: 2007-07-05 | |||||||||||
Sponsor Name:BEAUFOUR IPSEN PHARMA | |||||||||||||
Full Title: Phase III, multicentre, non comparative, open and single stage study to assess the efficacy and safety of pamoate of triptorelin 11.25 mg in children with precocious puberty | |||||||||||||
Medical condition: Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000565-39 | Sponsor Protocol Number: 2-54-52014-159 | Start Date*: 2008-04-18 | |||||||||||
Sponsor Name:BEAUFOUR IPSEN PHARMA | |||||||||||||
Full Title: FOLLOW-UP OF THE PHASE III, MULTICENTRE, NON COMPARATIVE, ONE SINGLE GROUP, OPEN STUDY TO ASSESS THE LONG-TERM EFFICACY AND TOLERABILITY OF PAMOATE OF TRIPTORELIN 11.25 MG IN CHILDREN WITH PRECOCIO... | |||||||||||||
Medical condition: Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001607-30 | Sponsor Protocol Number: Debio8206-CPP-301 | Start Date*: 2015-04-24 | |||||||||||
Sponsor Name:Debiopharm International, S.A. | |||||||||||||
Full Title: An open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gon... | |||||||||||||
Medical condition: Central Precocious Puberty | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001180-77 | Sponsor Protocol Number: D6873C00047 | Start Date*: 2012-03-07 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: An open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio... | |||||||||||||
Medical condition: testotoxicosis (precocious puberty) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004536-28 | Sponsor Protocol Number: 1 | Start Date*: 2021-11-15 |
Sponsor Name:Uppsala University, Department of Women's and Children´s Health | ||
Full Title: Vaginal administration of selective estrogen receptor modulator (Tamoxifen) treatment to improve sexual function for women with breast cancer. A randomized, double-blinded, placebo controlled longi... | ||
Medical condition: Most troublesome vulvovaginal atrophy symptom | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000142-22 | Sponsor Protocol Number: 148-2016 | Start Date*: 2017-05-24 | |||||||||||
Sponsor Name:Helm AG | |||||||||||||
Full Title: Assessment of therapeutical equivalence of a newly developed vaginal tablet containing 10 μg of estradiol in comparison with a marketed reference product (Vagifem®) – a double-blind, double-dummy, ... | |||||||||||||
Medical condition: Investigation of efficacy, safety and tolerability of estradiol vaginal tablets in postmenopausal women with vaginal atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000384-10 | Sponsor Protocol Number: D6873C00047 | Start Date*: 2005-03-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open-label, non-comparative, multi-centre study to assess the efficacy and safety of bicalutamide when used in combination with anastrozole for the treatment of gonadotropin-independent precocio... | |||||||||||||
Medical condition: testotoxicosis (familial male-limited gonadotropin-independent precocious puberty) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016492-29 | Sponsor Protocol Number: D3561C00002 | Start Date*: 2010-03-08 |
Sponsor Name:AstraZeneca AB | ||
Full Title: An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia | ||
Medical condition: Male and female children and adolescents (aged 6 to < 18 years) with FH* and at least 1 of the following criteria: 1. Fasting LDL-C>190 mg/dL (4.92 mmol/L) at baseline OR 2. Fasting LDL-C >160 ... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) BE (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-002325-30 | Sponsor Protocol Number: VMP-03/2018 | Start Date*: 2019-09-18 | |||||||||||
Sponsor Name:Dr. August Wolff GmbH & Co. KG Arzneimittel | |||||||||||||
Full Title: Prospective, open-label, monocenter, trial to investigate the efficacy and tolerability of Vagisan® a lactic acid containing vaginal suppository, in a panel of post-menopausal women suffering from... | |||||||||||||
Medical condition: vulvovaginal atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003857-78 | Sponsor Protocol Number: D-CN-52014-244 | Start Date*: 2023-06-29 |
Sponsor Name:Ipsen Pharma | ||
Full Title: A phase III, open-label, multicentre, single arm study to assess the efficacy and safety of the triptorelin 6-month formulation in Chinese paediatric participants with central precocious puberty | ||
Medical condition: Central Precocious Puberty | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-003120-17 | Sponsor Protocol Number: PDY16963 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: A 3-part study to evaluate the efficacy and safety of venglustat in combination with Cerezyme in adult and pediatric patients with Gaucher disease Type 3 (GD3) with open-label long-term treatment | |||||||||||||
Medical condition: Gaucher disease type 3 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-001104-33 | Sponsor Protocol Number: AT0071002 | Start Date*: 2023-12-22 | |||||||||||
Sponsor Name:Applied Therapeutics Inc. | |||||||||||||
Full Title: A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients with Classic Galactosemia (CG) | |||||||||||||
Medical condition: Galactosemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002340-90 | Sponsor Protocol Number: HPV-Xneutra-001 | Start Date*: 2013-06-26 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: Study of the molecular mechanisms underlying the cross-neutralizing capacity of AS04-adjuvanted HPV vaccine (Cervarix®) in comparison with the aluminiumhydroxyphosphate sulphate adjuvanted HPV vacc... | |||||||||||||
Medical condition: vaccin against the human papillomavirus | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004879-39 | Sponsor Protocol Number: IM011-126 | Start Date*: 2021-04-01 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS-986165 in Adolescent Subjects with Moderate to Severe Plaque Ps... | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004459-19 | Sponsor Protocol Number: CDRB436G2401 | Start Date*: 2019-07-31 |
Sponsor Name:Novartis Farmacéutica S.A. | ||
Full Title: An open label, multi-center roll-over study to assess long-term effect in pediatric patients treated with Tafinlar (dabrafenib) and/or Mekinist (trametinib) | ||
Medical condition: Children and Adolescents with Cancers Harboring V600 mutations | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005465-20 | Sponsor Protocol Number: OXYPEP002 | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:PeP-Tronic Medical AB | |||||||||||||
Full Title: A double-blind, placebo controlled single centre trial to evaluate the dose-relationship of the effects of vaginally administered oxytocin on the vaginal mucosal membrane in postmenopausal women | |||||||||||||
Medical condition: Vaginal atrophy in postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024603-26 | Sponsor Protocol Number: IEOS583/111 | Start Date*: 2011-09-09 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: A phase II study of low-dose vaginal estrogens in pre and postmenopausal breast cancer patients with urogenital atrophy | |||||||||||||
Medical condition: Pre- and postmenopausal women who are receiving adjuvant endocrine treatment (LH-RH analogue plus Tamoxifene or Aromatase Inhibitor, Tamoxifene alone, Aromatase Inhibitor alone) for early breast ca... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000158-36 | Sponsor Protocol Number: OXYPEP202 | Start Date*: 2016-03-18 | |||||||||||
Sponsor Name:PEPTONIC medical AB | |||||||||||||
Full Title: A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy | |||||||||||||
Medical condition: Vaginal Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004517-84 | Sponsor Protocol Number: ITFE-2026-C10 | Start Date*: 2015-02-26 |
Sponsor Name:ITF Research Pharma S.L.U | ||
Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ... | ||
Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Completed) SE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
